Context: Ocluzia intestinală de cauză malignă este o complicaţie frecventă la pacienţii cu cancer în stadii avansate. Prognosticul este slab, cu o rată medie de supravieţuire mai mică de 3 luni. Tratamentul clinic, procedurile endoscopice sau chirurgicale sunt opţiuni pentru managementul obstrucţiei intestinale maligne. Nu există o strategie de management general acceptată. Obiective: Evaluarea factorilor de prognostic ai pacienţilor cu obstrucţie intestinală malignă care au fost supuşi unui tratament chirurgical. Metode: A fost efectuată o analiză retrospectivă incluzând pacienţii unei singure instituţii medicale, cu diagnostic de obstrucţie intestinală malignă. Au fost evaluate datele demografice, perioada de internare, complicaţiile postoperatorii şi supravieţuirea globală. Regresia logistică a fost utilizată pentru evaluarea factorilor prognostici asociaţi. Rezultate: Două sute treizeci şi trei de intervenţii chirurgicale au fost efectuate datorită suspiciunii de obstrucţie intestinală malignă pe o perioadă de şapte ani. Acest diagnostic a fost confirmat în cazul a 210 intervenţii chirurgicale (90,1%). Principalele cauze ale obstrucţiei maligne au fost cancerul colorectal (49,5%) şi cancerul ginecologic (21,9%). Rata complicaţiilor severe a fost de 11,42%. Rata mortalităţii intraspitaliceşti a fost de 40,95% (interval de încredere 95%: 34,16-47,74%). Deficienţa funcţională, ureea serică crescută şi nivelurile scăzute de albumină au fost asociate cu o rată mai mare a mortalităţii.
Introduction
Malignant intestinal obstruction (MIO) is a common complication in advanced stages cancer patients. Currently, MIO is defined as clinical evidence of intestinal obstruction distal to Treitz ligament, with the presence of primary intra-abdominal neoplasm or extraabdominal cancer with peritonealdissemination (1) . The most frequent intra-abdominal neoplasms associated to MIO are colorectal and ovarian cancers (2) . Thereported prevalence is 24% in advanced colorectal cancer and 42% in advanced ovarian cancers (3, 4) . Breast cancer and melanoma are the most frequent extra-abdominal cancers associated with MIO (5) .
Obstruction can be caused by several reasons including: extrinsic compression, with peritoneal implants compressing bowel loops; mural invasion with muscular intestinal wall spread can lead to impairment of motility; mesenteric or nervous plexus invasion can also lead to functional motility disorders (6) .
The most common symptoms are nausea (100% of the cases), vomiting (87-100% of the cases), abdominal pain (72-80%), abdominal distension (56-90%) and no flatus or stool elimination in the last 72 hours (85-93%) (7) .
MIO prognosis is usually poor, regardless of the chosen therapeutic strategy. The mean survival rate is around 3 months (8) , and the mortality is 80% higher compared to benign intestinal obstruction (9) . MIO management is multimodal. Clinical initial management is based on fasting, parental hydration, nasogastric decompression, symptomatic drugs, corticoids, and antisecretory drugs (7) . Management can also be performed with palliative chemotherapy; or patients can be treated by endoscopic stents and surgical procedures. Choosing the best management strategy is a great challenge, since patients with MIO usually have poor oncologic prognosis and are frail and functionally impaired (8) .
Surgical intervention is generally indicated only after clinical management failure, or worsening clinical condition, and aims to reestablish intestinal transit. Nonetheless, surgical treatment is the modality with the best results for intestinal deobstruction (10) .
Thus, this study aimed to perform a descriptive analysis of patients with MIO who underwent surgical intervention, and to analyze prognostic factors associated with MIO. 
Methods

Results
In the period 2009-2016, 1,953 exploratory laparotomies were performed, of which 233 were performed due to suspected MIO (11.9%). In 210 surgeries, suspected MIO was confirmed after surgery (90.1%), and the remaining cases presented with obstruction of benign intraabdominal origin.
The main primary neoplasm associated with MIO was colorectal (49.5%),followed by gynecological (21.9%), as shown in Fig. 1 .
The postoperative in-hospital mortality rate was 40.95% (CI 95%:34.16-47.74%). Of those patients that were discharged, the 30-day mortality rate was 21.3% (CI 95%: 5.7-17%). Patients with benign obstruction had a postoperative in-hospital mortality of 13.1% (CI 95%:3.8-22.4%). Of those that were discharged, the 30-day mortality rate was null.
The 360-day overall survival in patients with malignant obstruction was 16.4%. In patients with benign obstruction, this rate was 62% and differences between the survival curves were statistically significant (p<0.001). The overall survival curvescan be seen in Fig. 2 .
The patients' characteristics with malignant obstruction can be seen in Table 1 . The mean follow-up was 17.5 months (SD 16,05).
At the time of MIO diagnosis, 21.9% had pulmonary metastasis and 29% had liver metastasis.At this point, most patients had previous history of any other treatment for cancer: 86.7% had previous history of surgery, 83.8% was previously submitted to systemic chemotherapy and 22.8% was previously submitted to radiotherapy.
The anatomical obstruction position was in small bowel in 77.6%, and the remaining colon was affected. Therefore, the most used tactical surgery approach was intestinal bypass (20.48%), enterectomy (18.57%), and loop ileostomy (17.62%). No anastomosis was performed in most of the cases (55.70%). Non-therapeutic laparotomy occurred in 14.3% of the cases, generally due to high level of intra-abdominal adhesions, with the aspect of "frozen abdomen". See Table 2 .
The mean length of clinical management Table 3 . The most frequent severe surgical complication was anastomosis leakage, followed by evisceration or eventration. The in-hospital mortality of patients that presented severe complications was 75%.
Among 86 patients who died during hospitalization, the most frequent cause of death was due to the intestinal obstruction itself, either due to impossibility to perform surgery (nontherapeutic laparotomy) or due to the inefficient surgical procedure. Other common complications were sepsis and surgical complications. See Table 4 .
To discriminate survival predictors factors, Odds Ratio (OR) were calculated for in-hospital stay mortality, and the 30-, 90-and 180-day mortality. The primary neoplasm was individually assessed and two groups were analyzed (colorectal and gynecological cancer vs. other neoplasm). The colorectal and gynecological cancer group showed a statistically significant lowerprobability for mortality than other neoplasms in the 90-day (OR: 2.95) and 180-day (OR: 3.06), as seen in Table 5 .
The type of surgical procedure did not show any association with mortality, otherwise, nontherapeutic surgery led to a higher risk for mortality. See Table 6 . A logistic regression was performed to assess clinical and laboratorial patients' characteristics associated to in-hospital mortality, and 30-, 90-and 180-day mortality. KPS was associated with the outcome in all assessed periods. Serum urea, C-reactive protein, and albumin were associated to higher mortality during inhospital stay and in 30 days, and serum albumin was associated to higher mortality in 90 days as well. Hemoglobin were associated to higher mortality in 90 and 180 days. See Table 7 and 8.
Discussion
Patients with MIO show poor prognosis, with low survival rates. In this study, the 360-day survival rate was 16.4%. Postoperative inhospital mortality rate was 40.95%. Previous reports also presented high mortality rate, with 30-day postoperative mortality ranging 6-32% (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) .
The main cause of death in operated patients was intestinal obstruction itself, in cases where nothing could be done in the surgery or in which surgery was unsuccessful. Thus, usually palliative care is the mainstay in the management of patients with MIO. In this case, the relief of symptoms such as nausea, cramps, distension and abdominal discomfort are the priorities. The surgical decision should always be considered, since it is the most effective approach in clearing intestinal obstruction or even in symptoms palliation. Also, surgery may improve survival in these cases (14, 20, 26) . However, caution should be taken, once there is high probability for nontherapeutic laparotomy, due to the so-called "frozen abdomen", in which surgery is technically impossible. In addition, due to the high risk for severe complications, this decision should be carefully considered on a case-by-case and individualized basis. In this study, the incidence of severe postoperative complications was 11.42%. In other casuistries the incidence of severe complications ranged from 7 to 44% (12) (13) (14) (15) 17, (18) (19) (20) (21) (22) (23) (24) (25) 26) .
Before deciding for surgery, prognostic factors of each patient should be evaluated. Variables such as age, nutrition and functional performance status should be taken into account, even in cases where surgery is technically feasible (3, 27) .
Postoperative mortality in patients with nutritional deficiency and hypoalbuminemia is known to be higher (5, 6) . In our study, hypoalbuminemia was associated with higher in-hospital mortality and higher 90-day mortality. The use of parenteral nutrition during the perioperative period, while questionable in palliative patients (28) , should be considered in selected cases.
Although the presence of ascites did not show a significant difference for mortality in this study, some studies have shown that refractory ascites may be associated with worse postoperative results and should be taken into consideration as prognostic factor, mainly when their volume exceeds 3000 cc3 (15, 29) .
In the univariate analysis, chemotherapy prior to surgery was associated with higher postoperative mortality. Other studies have shown similar findings (30, 31) . Such findings may be justified becausein patients with advanced cancer undergoing chemotherapy, progression to MIO frequently is progression of the disease, which no longer responds to the first lines of palliative chemotherapy (32) .
As a limitation of this retrospective study, the high number of uncontrolled variables, the absence of well-establishedpre-specified protocol for operative intervention, and the heterogeneous casuistry (regarding clinical www.revistachirurgia.ro Chirurgia, 114 (3), 2019
J.H. Bento de Sousa et al status and characteristics of each neoplasm) increase the risk of bias. However, in the lack of controlled clinical trials, this study can be supportive to MIO patient evaluation to provide the best therapeutic option. Treatment should be multidisciplinary in patients with malignant bowel obstruction, with the participation of oncology, surgery, nutrology, psychology, palliative care team, among others. Also crucial is the participation of patients and their families when deciding on therapeutic strategies. Patients and family members should be aware of the prognostic factors, risks of complications and probability of non-resolution of the condition, even with interventional measures such as surgical procedures.
Conclusions
MIO implies poor prognosis, with high inhospital mortality rate and severe postoperative complications. Under nourishment, anemia, renal failure and low performance status are associated to high mortality.The decision regarding management of MIO must be multimodal and individualized, according to individual prognostic factors.
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